The future of precision medicine part 1: challenges and opportunities
The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Allen & Overy discusses the issues around translating the promise of precision medicine into real world clinical practice.
Latest news
USFDA to modernise generic review with $37.6m funding
19-06-2018
The US Food and Drug Administration is planning to use new budget funding to modernise generic drug review and promote more widespread use of generics.
50 Key Influencers In The Life Sciences
Regions
